Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 813-399-9 | CAS number: 1821694-26-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation
- Remarks:
- in vivo
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable well-documented peer-reviewed report.
Data source
Reference
- Reference Type:
- publication
- Title:
- Final Report of the Safety Assessment of L-Ascorbic Acid, Calcium Ascorbate, Magnesium Ascorbate, Magnesium Ascorbyl Phosphate, Sodium Ascorbate, and Sodium Ascorbyl Phosphate as Used in Cosmetics.
- Author:
- CIR (Cosmetic Ingredient Review)
- Year:
- 2 005
- Bibliographic source:
- International Journal ofToxicolgy. 24 (Suppl. 2): 51-111, 2005.
Materials and methods
Test guideline
- Qualifier:
- no guideline required
- Principles of method if other than guideline:
- The report describes results of dermal application of creams containing Magnesium Ascorbyl Phosphate to prevent scurvy and dark pigmentation in guinea pigs and humans, respectively. The report concludes safety use of L-ascorbic acid and its magnesium, calcium and sodium salts in cosmetic products.
- GLP compliance:
- no
- Type of study:
- other: dermal application of cream containing magnesium ascorbyl phosphate to guinea pigs and humans.
- Justification for non-LLNA method:
- The study was conducted prior LLNA became as standard information requirement.
Test material
- Reference substance name:
- Magnesium ascorbate
- IUPAC Name:
- Magnesium ascorbate
- Reference substance name:
- Magnesium Ascorbyl Phosphate
- IUPAC Name:
- Magnesium Ascorbyl Phosphate
Constituent 1
Constituent 2
Results and discussion
In vivo (non-LLNA)
Results
- Reading:
- other: Evaluation of skin sensitisation potential of magnesium compounds in cosmetic formulations.
- Group:
- test chemical
- Dose level:
- Cosmetic formulations: 7.5 to 30.0 mg/day/animal or 10 % cream (humans/day)
- No. with + reactions:
- 0
- Total no. in group:
- 34
- Clinical observations:
- No overt skin reactions related to sensitisation
- Remarks on result:
- other:
- Remarks:
- Magnesium salts of ascorbic acid (Magnesium Ascorbate, Magnesium Ascorbyl Phosphate, Sodium Ascorbate) are evaluated to be safe as used in cosmetic products. The Panel concluded that these magnesium salts are not sensitizing in human subjects.
Any other information on results incl. tables
Imai et al. (1967) administered either a stock diet or a scorbutigenic diet and water ad libitum for 10 days to male guinea pigs. Guinea pigs fed the scorbutigenic diet were divided into groups after the 10-day feeding period and were percutaneously given Ascorbic Acid at doses from 3.5 to 14.0 mg/day or Magnesium Ascorbyl Phosphate at doses from 7.5 to 30.0 mg/day, both in a cream. The cream was applied on the clipped skin of the back just posterior to the neck. The cream base consisted of cetyl alcohol 3%, hydrogenated lanolin 4%, vegetable oil such as olive oil 3%, isopropyl myristate 6%, polyethylene glycol 6%, nonionic surface-active agents such as polyoxyethylene stearate and glycerol monostearate 16%, and preservatives. One-third the daily dose of the cream was applied at 8 AM, 12 PM, and 4 PM. After application the animals were observed. The L-Ascorbic Acid dose of 7 mg/animal/day (0.5 g cream/ day) and 15 mg/animal/day of Magnesium Ascorbyl Phosphate (0.5 g cream/day) prevented the development of scurvy; the activity of Magnesium Ascorbyl Phosphate was somewhat weaker than that of L-Ascorbic Acid. Sixteen hours after the last application of cream, the skin of the back (treated) and of the abdomen (non-treated) were examined microscopically. The applied skin of the backs in the treated groups indicated the existence of Ascorbic Acid in the intercellular space of the epithelium, contrasting with the absence of Ascorbic Acid in the control group and in the skin of the abdomen in all groups (Imai et al. 1967).
Magnesium Ascorbyl Phosphate Magnesium Ascorbyl Phosphate (VC-PMG) cream (10%) was applied twice a day to the skin of 34 patients with ephelides, chloasma, senile freckles, nevus of Ota, or healthy skin. The effectiveness of the lightening of the pigmentation was judged by a color-difference meter. The VC-PMG cream was effective or fairly effective in 19 of 34 patients. VC-PMG cream applied to the healthy skin of 25 patients resulted in 1 effective, 2 fairly effective, 8 slightly effective, 12 not effective, and 2 possible darkenings (Kameyama et al. 1996).
Applicant's summary and conclusion
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: expert judgment
- Conclusions:
- Magnesium salts of ascorbic acid (Magnesium Ascorbate, Magnesium Ascorbyl Phosphate, Sodium Ascorbate) are evaluated to be safe as used in cosmetic products. The Panel concluded that these magnesium salts are not sensitizing in human subjects.
- Executive summary:
Magnesium Ascorbate is described as antioxidant and skin conditioning agent and Magnesium Ascorbyl Phosphate is an antioxidant in cosmetic products. The concentration of use in cosmetics is reported to be in the range of 0.001 -3%.
Magnesium Ascorbyl Phosphate (7.5 to 30 mg/animal/day (= 0.5 g cream/day)) administered dermally, prevented the development of scurvy in guinea pigs fed by scorbutigenic diet. No skin sensitisation reactions were reported due to the administration of this magnesium salt in treated animals. Magnesium Ascorbyl Phosphate (10 % as lightening cream) was tested in patients with different skin disorders and in healthy patients. No skin sensitization reactions were reported.
Because of the structural and functional similarities of the ingredients: L-Ascorbic Acid, Calcium Ascorbate, Magnesium Ascorbate, Magnesium Ascorbyl Phosphate, Sodium Ascorbate, and Sodium Ascorbyl Phosphate, the Panel believes that the data on one ingredient can be extrapolated to all of them.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.